Business
Notice of Interim Results & Investor Presentation
Ondine Biomedical Inc. will release its unaudited interim financial results for the period ending June 30, 2025, on September 26, 2025. A live presentation regarding these Half Year Results will be given by the President and Interim Chief Financial Officer via Investor Meet Company on the same day at 16:30 BST. The company encourages existing and potential shareholders to participate, with questions accepted before and during the event until September 25, 2025, at 09:00 BST. Interested parties can register for free on the Investor Meet Company platform to access the presentation. Disclaimer*
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n19 September 2025\nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\nNotice of Interim Results and Investor Presentation\nOndine Biomedical Inc. (AIM: OBI) announces that it will publish its unaudited interim financial results for the period ended 30 June 2025 (\"Half Year Results\") on 26 September 2025.\nDr. Nicolas Loebel, President and Chief Technology Officer, and Alan Thomas, Interim Chief Financial Officer, of the Company, will provide a live presentation relating to the Half Year Results via Investor Meet Company on 26 September 2025 at 16:30 BST (08:30 Pacific time).\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 25 September 2025, 09:00 BST (01:00 Pacific time), or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet ONDINE BIOMEDICAL INC. via: \nhttps://www.investormeetcompany.com/ondine-biomedical-inc/register-investor\nInvestors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet Company platform will automatically be invited.\n \nEnquiries:\n\n\n\n\nOndine Biomedical Inc.\n\n\nwww.ondinebio.com\n\n\n\n\nCarolyn Cross, CEO \n\n\n+1 604 669 0555\nor via Vane Percy & Roberts\n\n\n\n\n \nStrand Hanson Limited (Nominated & Joint Financial Adviser)\n\n\n\n\n\n\n\nJames Harris, Richard Johnson\n\n\n+44 (0)20 7409 3494\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP (Broker & Joint Financial Advisor)\n\n\n\n\n\n\n\nJames Steel, Dr. Chris Golden\n\n\n+44 (0)20 7418 8900\n\n\n\n\n\n\n\n\n\n\n\n\nVane Percy & Roberts (Media Contact)\n\n\n\n\n\n\n\nSimon Vane Percy\n\n\n+44 (0)77 1000 5910\n\n\n\n\n \n \nAbout Ondine Biomedical Inc.\n \nOndine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.\n \nOndine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Di...